We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

12 hedge funds and large institutions have $192K invested in AIM ImmunoTech in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.38% less ownership

Funds ownership: 2.85% → 2.48% (-0.38%)

8% less funds holding

Funds holding: 13 → 12 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

46% less capital inflows, than outflows

Capital inflows: $37.4K | Capital outflows: $69.4K

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$22.3K
2
Virtu Financial
Virtu Financial
New York
+$13.4K
3
Advisor Group
Advisor Group
Arizona
+$890

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$26K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$16.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11K
4
Paloma Partners
Paloma Partners
Connecticut
-$9K
5
Two Sigma Securities
Two Sigma Securities
New York
-$4.45K

AIM Hedge Fund Activity: Q1 2019 in Review

12 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2019, worth a combined $192K — down 23% from $248K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of AIM and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $22.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $26K sold.

  • 12 institutional investors held AIM ImmunoTech (AIM) as of Q1 2019, down from 13 in Q4 2018.
  • Funds reported $192K of AIM ImmunoTech stock for Q1 2019, down 23% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q1 2019 and 4 closed out, a net change of -1 holder.
  • The largest AIM ImmunoTech buyer in Q1 2019 was UBS Group, an estimated $22.3K added.
  • The largest AIM ImmunoTech seller in Q1 2019 was Citadel Advisors, an estimated $26K sold.

Based on aggregated 13F filings for Q1 2019.